IA
CRSP icon

Integrity Advisory’s CRISPR Therapeutics CRSP Stock Holding History

Integrity Advisory’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,687
Closed -$241K – 78
2022
Q3 		$241K Sell
3,687
-1,387
-27% -$101K 0.22% 64
2022
Q2 		$308K Buy
5,074
+275
+6% +$16.2K 0.3% 54
2022
Q1 		$301K Buy
+4,799
New +$301K 0.3% 60

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Integrity Advisory's CRSP Position: Q4 2022 in Review

Integrity Advisory sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 3,687 shares — an estimated $241K sold.

Integrity Advisory first reported a position in CRSP in Q1 2022 and held it in 3 quarters. The position peaked at $308K in Q2 2022. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

  • Integrity Advisory reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Integrity Advisory sold 3,687 CRISPR Therapeutics shares in Q4 2022, an estimated $241K.
  • Integrity Advisory first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 3 quarters.
  • Integrity Advisory's CRISPR Therapeutics position peaked at $308K in Q2 2022.
  • 398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on Integrity Advisory's 13F filing for Q4 2022, filed 24 Jan 2023.